Elotuzumab: new immune-stimulating myeloma treatment

Elotuzumab (Empliciti) is an immunostimulatory antibody that promotes the killing of myeloma cells by natural killer cells. It targets the cell-surface receptor SLAMF7.

Elotuzumab directly activates natural killer cells. | SCIENCE PHOTO LIBRARY
Elotuzumab directly activates natural killer cells. | SCIENCE PHOTO LIBRARY

Empliciti is indicated in combination with lenalidomide and dexamethasone to treat multiple myeloma in patients who have received at least one prior therapy.

Further information
View Empliciti drug record
Summary of Product Characteristics
Manufacturer: BMS

In a randomised open-label phase III trial in 646 patients with relapsed or refractory multiple myeloma, addition of elotuzumab to lenalidomide and dexamethasone treatment produced a significant relative reduction of 30% in the risk of disease progression or death. Median progression-free survival in the elotuzumab group was 19.4 months, compared with 14.9 months in the control group (p<0.001).

The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (p<0.001).

Before being treated with elotuzumab, patients must receive premedication with dexamethasone, an H1 blocker, an H2 blocker and paracetamol to reduce the risk of infusion reactions. Other very common adverse events seen with the antibody in clinical trials were diarrhoea, herpes zoster, nasopharyngitis, cough, pneumonia, upper respiratory tract infection, lymphopenia and weight loss. The most serious adverse reaction that can occur during treatment is pneumonia. 

 


Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Multiple myeloma

Multiple myeloma

Clinical features, investigations, management and the...

Carfilzomib:  new treatment for multiple myeloma

Carfilzomib: new treatment for multiple myeloma

Carfilzomib (Kyprolis) in combination with lenalidomide...

Case study - Diagnosing multiple myeloma

Case study - Diagnosing multiple myeloma

A case of self-diagnosed arthritis was found to be...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases